Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117977 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14118106 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL15579829 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL13146811 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL13146839 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14117968 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL13146823 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14117971 | 1.00 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL13146853 | 0.97 | GLP1R (0.68) | GLP1RFOLH1NOD1 | |
| SCHEMBL13146867 | 0.97 | GLP1R (0.68) | GLP1RFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | GLP1R 134/4885FOLH1 2002/4885NOD1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.